Oncotarget

Research Papers:

Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma

Guojun Hou, Gang Liu, Yuan Yang, Yixue Li, Shengxian Yuan, Linghao Zhao, Mengchao Wu, Lei Liu and Weiping Zhou _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:64957-64966. https://doi.org/10.18632/oncotarget.11778

Metrics: HTML 906 views  |   ?  


Abstract

Guojun Hou1,*, Gang Liu2,3,*, Yuan Yang1,*, Yixue Li2, Shengxian Yuan1, Linghao Zhao1, Mengchao Wu4, Lei Liu3, Weiping Zhou1

1The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

2Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China

3Institute of Biomedical Sciences, Fudan University, Shanghai, China

4The Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China

*These authors have contributed equally to this work

Correspondence to:

Weiping Zhou, email: ehphwp3@126.com

Lei Liu, email: liulei_sibs@163.com

Keywords: neuraminidase 1, hepatocellular carcinoma, prognosis, migration, proliferation

Received: May 18, 2016    Accepted: August 13, 2016    Published: September 01, 2016

ABSTRACT

Hepatocellular carcinoma (HCC) is among the most malignant cancers worldwide, lacking biomarkers for subtyping and the reliable prognostication. Herein, we report a novel biomarker, NEU1 (neuraminidase 1), is up-regulated in most samples of HCC. The diagnostic value of NEU1 was evaluated by ROC, and the AUC (area under curve) reached 0.87 and 0.96 in two independent datasets, respectively. The survival differences of HCC patients with high or low expression of NEU1 were statistically significant, and a significant correlation between NEU1 expression and clinical information including stage, differentiation, AFP and embolus were observed. NEU1 expression, at both the mRNA and protein levels, were also higher in the portal vein tumor thrombus than tumor tissues. We also measured the proliferation and migration ability of two HCC cell lines following NEU1 interference and over-expression. Migration and proliferation rate were increased in NEU1 high expression groups. Moreover, gene expression studies identified pathways significantly associated with NEU1 expression. Among them, all the genes involved in spliceosomepathway were up regulated in NEU1-high group. In summary, our work identified NEU1 as a novel biomarker for both diagnosis and prognosis in HCC, and one of the most altered pathway of NEU1 is spliceosome.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11778